Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Registry maps the return of a stubborn heart condition

NCT ID NCT06517966

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

Researchers are building a registry to follow adults with recurrent pericarditis, a condition where inflammation around the heart keeps coming back. The registry collects information over time on how often flare-ups happen, what treatments patients receive, and whether they are hospitalized. It does not test a new drug; instead, it aims to describe how the condition and its care unfold in everyday practice across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the registry succeeds, it could give doctors a clearer picture of how recurrent pericarditis behaves over time and which treatment approaches help most.
What could go wrong
This is an observational registry, not a treatment trial, so it cannot prove that any therapy works. It depends on routine records and follow-up visits, which may be incomplete or vary between hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Anonymous male and female patients over 18 years of age suffering from recurrent pericarditis without an established etiology at the time of inclusion in the study (suspected "idiopathic recurrent pericarditis") or diagnosed with "idiopathic recurrent pericarditis"

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Men or women 18 years of age or older at the time of data recording or pericarditis debut; 2. Presence of one of the following conditions: * a specialist-confirmed diagnosis of recurrent pericarditis without an established etiology at the time of inclusion in the study (suspected "idiopathic recurrent pericarditis"); * a specialist-confirmed diagnosis of "idiopathic recurrent pericarditis". Exclusion Criteria: 1. Age below 18 years at the time of inclusion in the registry or debut of pericarditis; 2. Specialist-confirmed secondary genesis of RP (infectious, autoimmune, neoplastic, metabolic, traumatic, iatrogenic, etc.); 2. Manifestations and complications of myocarditis, various diseases of thoracic organs, systemic diseases, cardiac surgery, radiation therapy, tuberculosis, etc.); 3. lack of possibility of screening examination and dynamic follow-up; 4. Organ/tissue transplantation less than 5 years prior to study inclusion or debut of pericarditis; 5. Oncologic disease less than 3 years prior to study inclusion or pericarditis debut; 6. Chemotherapy with anthracycline-type drugs at the time of pericarditis debut; 7. Administration of amphetamine-type drugs at the time of pericarditis debut; 8. Cardiac/pericardial surgery in the last 6 months prior to study inclusion or pericarditis debut; 9. Myocardial infarction in the last 3 months prior to study inclusion or debut of pericarditis; 10. Traumatic chest injury in the last 3 months prior to study inclusion or pericarditis debut; 11. Absence of an informed consent form signed by the patient for participation in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Idiopathic recurrent pericarditis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Eurasian Association of Therapists

    Moscow, 11000, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.